BioPharma

Alder BioPharmaceuticals announced that Randall Schatzman, the company’s president, chief executive officer and director, will be stepping down. Source: BioSpace

AstraZeneca’s drug Farxiga could receive a new indication for a subset of diabetes patients based on Phase III data that was released today. Source: BioSpace

The FDA granted a Priority Review designation to Pfizer and partner Astellas Pharma for expanded use of Xtandi in prostrate cancer treatment. Source: BioSpace

Gilead Sciences essentially created a cure for hepatitis C and may be well on its way to developing a cure for HIV-AIDS. Source: BioSpace

Arena Pharmaceuticals released positive top-line results from its Phase II trial of etrasimod in ulcerative colitis. Source: BioSpace

Ocugen announced this morning that its mid-stage combination treatment hit its primary endpoint of tolerability in a proof-of-concept trial. Source: BioSpace

Cidara Therapeutics reported its mid-stage antifungal candidate hit its primary endpoints and is on track to begin Phase III testing later this year. Source: BioSpace

In the world of politics and civil rights, the ideas of gender and transgender have been a hot-button issue. But a new study suggests that transgender people may have a genetic disposition that influences their identity. Source: BioSpace

Here are six biotech companies that should benefit the most from research-and-development spending trends that are expected to stimulate biotech development. Source: BioSpace

Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease. Source: BioSpace